Sotrovimab resistance and viral persistence after treatment of immunocompromised patients infected with the SARS-CoV-2 Omicron variant.

Sammy HuygensBas Oude MunninkArvind GharbharanMarion P G KoopmansBart Rijnders

Published in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022)

Viral evolution was evaluated in 47 immunocompromised patients treated with sotrovimab. Sequencing of SARS-CoV-2 following therapy was successful in 16. Mutations associated with sotrovimab resistance were documented in 6, viral replication continued after 30 days in 5. Combination antibody therapy may be required to avoid acquired resistance in immunocompromised patients.

Keyphrases

sars cov
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
respiratory syndrome coronavirus
stem cells
intensive care unit
coronavirus disease
smoking cessation